Evaluation of Commercial and Purified Pluronic® F-68 In A Human Blood Neutrophil Bioassay

References

• Lowe K. C. Perfluorochemicals in vascular medicine. Vase. Med. Rev. 1994; 5: 15–32
   Google Scholar
• Zuck T. F., Riess J. G. Current status of injectable oxygen carriers. Crit, Rev. Clin. Lab. Sci. 1994; 31: 295–324
   PubMed Web of Science ®Google Scholar
• Lowe K. C. Perfluorochemical respiratory gas carriers: applications in medicine and biotechology. Science Prog. 1997; 80: 169–193
   PubMedGoogle Scholar
• Ingram D. A., Forman M.B., Murray J. J. Phagocytic activation of human neutrophils by the detergent component of Fluosol. Am. J. Pathol. 1992; 140: 1081–1087
   PubMed Web of Science ®Google Scholar
• Ingram D. A., Forman M. B., Murray J. J. Activation of complement by Fluosol attributable to the Pluronic detergent micelle structure. J. Cardiovasc. Pharmacol. 1992; 22: 456–461
   Web of Science ®Google Scholar
• Forman M. B., Ingram D. A., Murray J. J. Attenuation of myocardial reperfusion injury by perfluorochemical emulsions. Clin. Hemorheol. 1992; 12: 121–140
   Google Scholar
• Forman M. B., Pitarys C. J., Vildibill H. D., Lambert T. L., Ingram D. A., Virmani R., Murray J. J. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion. J. Am. Coll. Cardiol. 1992; 19: 205–216
   PubMed Web of Science ®Google Scholar
• Schaer G. L., Hurscy T. L., Abrahams S. L., Buddcmeier K., Ennis B., Rodriguez R., Hubbell J. P., Moy J., Parrillo J. E. Reduction in reperfusion-induced myocardial injury in dogs by RheothRx Injection (Poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function. Circulation 1994; 90: 2964–2975
   PubMed Web of Science ®Google Scholar
• Schaer G. L., Spaccavento L. J., Browne K. F., Krueger K. A., Krichbaum D., Phelan J. M., Fletcher W. O., Grines C. L., Edwards S., Jolly M. K., Gibbons R. J. Beneficial effects of RheothRx Injection in patients receivinf thrombolytic therapy for acute myocardial infarction. Circulation 1996; 94: 298–307
   PubMedGoogle Scholar
• Riess J. G., Lc Blanc M. Preparation of perfluorochemical emulsions for biomedical use: principles, materials and methods. Blood Substitutes: Preparation, Physiology and Medical Applications, K.C. Lowe. Ellis Horwood, Chichester 1988; 94–129
   Google Scholar
• Bentlcy P. K., Davis S. S., Johnson O. L., Lowe K. C., Washington C. Purification of Pluronic F-68 for perfluorochemical emulsification. J. Pharm. Pharmac. 1989; 41: 661–663
   PubMed Web of Science ®Google Scholar
• Neilson C. P., Crowley J. J., Vestal R. E., Connolly M. J. Impaired beta-adrenoceptor function, increased leukocyte respiratory burst, and bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 1992; 90: 825–832
   PubMed Web of Science ®Google Scholar
• Lane T. A., Krukonis V. Reduction in the toxicity of a component of an artificial blood substitute by supercritical fluid fractionation. Transfusion 1988; 28: 375–378
   PubMed Web of Science ®Google Scholar
• Edwards CM., Lowe K.C., Trabelsi H., Lucas P., Cambon A. Novel fluorinated surfactants for perfluorochemical cmulsification: biocompatibility assessments of glycosidic and polyol derivatives. Art. Cells, Blood Subs., and Immob. Biotech. 1997; 25: 255–260
   PubMed Web of Science ®Google Scholar
• Snedecor G. W., Cochran W. G. Statistical Methods8th Edn. Iowa Stale College Press, Ames 1989
   Google Scholar
• Cawrse N. W., De Pomerai D. I., Lowe K. C. Effects of Pluronic F-68 on 2-deoxyglucose uptake and amino acid incorporation into chick embryonic fibroblasts in vitro. Biomed. Sci. 1991; 2: 180–182
   PubMedGoogle Scholar
• King A. T., Davey M. R., Mellor I. R., Mulligan B. J., Lowe K. C. Surfactant effects on yeast cells. Enzyme Microb. Technol. 1991; 13: 148–153
   Web of Science ®Google Scholar
• ICI Surfactant Data Sheet, ‘Synperonic’ PE/F68, TPDS7KB2. 1994
   Google Scholar
• Smith T. M., Stcinhorn D. M., Thusu K., Fuhrman B. P., Dandona P. A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages. Crit. Care Med. 1995; 23: 1533–1539
   PubMed Web of Science ®Google Scholar